O
VNDA icon

OrbiMed’s Vanda Pharmaceuticals VNDA Stock Holding History

OrbiMed’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-967,859
Closed -$14.7M – 149
2017
Q4 		$14.7M Hold
967,859
– – 0.19% 88
2017
Q3 		$17.3M Hold
967,859
– – 0.17% 89
2017
Q2 		$15.8M Buy
967,859
+917,659
+1,828% +$13.2M 0.17% 86
2017
Q1 		$703K Buy
+50,200
New +$715K 0.01% 131
2014
Q3 		– Sell
-455,000
Closed -$7.36M – 143
2014
Q2 		$7.36M Sell
455,000
-7,400
-2% -$98.6K 0.09% 98
2014
Q1 		$7.51M Sell
462,400
-527,600
-53% -$7.5M 0.09% 103
2013
Q4 		$12.3M Buy
+990,000
New +$9.94M 0.18% 76

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed's VNDA Position: Q1 2018 in Review

OrbiMed sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 967,859 shares — an estimated $14.7M sold.

OrbiMed first reported a position in VNDA in Q4 2013 and held it in 7 quarters. The position peaked at $17.3M in Q3 2017. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

  • OrbiMed reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • OrbiMed sold 967,859 Vanda Pharmaceuticals shares in Q1 2018, an estimated $14.7M.
  • OrbiMed first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 7 quarters.
  • OrbiMed's Vanda Pharmaceuticals position peaked at $17.3M in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.